Past studies have revealed that there is a link between type 2 diabetes mellitus (T2DM) and cardiovascular disease. This condition affects the health outcomes of many patients across the globe. Medical professionals have, therefore, been focusing on drugs that are capable of managing this illness. The cardiovascular benefits of GLP-1 receptor agonists can be identified in order to support more T2DM patients and make it easier for them to achieve their potential.
A qualitative study focusing on articles published within the past five years will be used. The insights gained from different documents will be used to compose meaningful discussions. Several insights have been researched and identified before completing the proposed study. For instance, past researches have outlined the following benefits of GLP-1 receptor agonists: weight loss, minimized chronic cardiovascular inflammation, and cardiovascular events.
Additionally, the risk for hypoglycemia and myocardial infarction reduces when T2DM patients use GLP-1 receptor agonists. The proposed study is, therefore, significant since the presented concepts will empower more practitioners to meet the needs of every T2DM patient. The research is also expected to transform medical practice by ensuring that the outlined cardiovascular benefits are available to more people with T2DM. Finally, the report will also encourage health leaders (HLs) to support their followers and improve the outcomes of their respective patients.